Catalyst Wire Dossier Catalyst Wire Dossier

rivoceranib mesylate

rivoceranib · Jiangsu HengRui Medicine Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for rivoceranib mesylate, covering 2022-09-01 to 2022-09-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 3]

See pricing